Today (May 8) morning, Hubei Donghu Science City · Big Health and Biotechnology Industry Base (Optics Valley Innovative Medicine Industry Base) was officially launched. According to the plan, by 2025, the total industrial output value of innovative drug companies will exceed 50 billion yuan, 5 innovative drug companies will be listed in the mainstream capital market, and 10 first-class new drugs will be approved for listing.
The Optics Valley innovative drug industry base with a planned layout of about 8,000 mu is based on the existing industrial foundation of Optics Valley Bio-city, aiming at the long-term, high With the characteristics of investment and light assets, it will focus on planning the spatial layout of the “three areas” linked by the core area of innovative drug research and development, the carrying area of large health and biotechnology industries, and the development area of international frontier biotechnology.
On-site signing ceremony
At the event site, a group of projects such as the global R&D headquarters of Renfu Medicine and the R&D and production base of Hansi Biopharmaceuticals were signed and settled. Wuhan Youzhiyou, a wholly-owned subsidiary of Wuhan Youzhiyou Biopharmaceuticals, plans to invest 360 million yuan to build the R&D and industrialization of the new crown recombinant protein vaccine (hereinafter referred to as “Y2019”) at the base. The project is expected to be put into production within 2 years.
Yi Jizu, senior vice president of Youzhiyou, introduced that at present, Y2019 has completed the first batch of vaccinations in Hubei CDC, and preliminary research The results showed that the vaccine was safe. “This product fills the gap in the field of COVID-19 vaccines in Hubei Province. It has the characteristics of high yield, low cost, high safety and good efficacy. The serum of the immunized animals is resistant to the original strain of the new coronavirus and various mutant strains. It has a cross-neutralizing effect. After the project is put into production, it can provide more than 100 million vaccines per year.”
Has taken root Wuhan Kefu New Drug Co., Ltd., which has been in Optics Valley for more than ten years, plans to continue to “overweight” Optics Valley, and plans to invest 120 million yuan to build a multi-functional nano preparation pilot and industrialization platform at the base, and promote the first development of high-end nano preparations such as pediatrics and ophthalmology. R&D and industrialization of imitation and improved new drugs. Zhou Xiaoshun, founder of Kefu New Drug: “The upstream and downstream resources here are very rich, whether it is the front-end small molecule pharmaceutical research and development services, the back-end animal experiments and safety evaluation, as well as the production supporting industrial conditions, the bio-industry of Optics Valley has formed A very good industrial structure chain.”
Wuhan Donghu High-tech Zone has obvious characteristics of biotechnology cluster, and the comprehensive strength of biomedicine is high. It ranks in the forefront of the national high-tech zone and the first in the central region. At present, Optics Valley has concentrated more than 400 pipelines of Class 1 new drugs under development, of which more than 40 new Class 1 drugs have entered the clinic.
Spatial layout of Optics Valley Innovative Drug Industry Base
< /p>
According to the development plan, by 2025, the total industrial output value of innovative drug companies will exceed 50 billion yuan, 10 top academicians and experts in the field of innovative drugs will be introduced, and 5 innovative drug companies will enter the mainstream In the capital market, 10 Class I new drugs were approved for listing. With Hubei East Lake Science City as the core, an innovative drug industry base with active innovation atmosphere, smooth achievement transformation, perfect supply chain and high-quality policy environment will be built, which will lay the foundation for East Lake Science City to build a global life and health science and technology innovation center.
In order to ensure the realization of the goal, Optics Valley launched “20 items for the development of innovative drug industry”, with precise efforts and special support. Among them, Wuhan East Lake High-tech Zone pioneered the “New Drug Creation Partner” model in the country to fund forward moves and share risks. For example, the annual subsidy of up to 20 million yuan per year for the clinical research cost of a single type of innovative drug, and the maximum subsidy for a single type of drug is 100 million yuan. For the research and development of improved new drugs and other drugs, the cumulative maximum subsidy for a single variety is 25 million yuan. For breakthroughs in the annual sales revenue of a single product, a cumulative reward of 6.5 million yuan will be given in a step-by-step manner. There are corresponding incentives and subsidies for generic drug consistency evaluation, clinical and post-marketing commercial insurance, and product international qualification certification.
Qian Deping, executive deputy director of Wuhan National Bio-Industry Base Construction Management Office, said that after more than ten years of development, the construction of Optics Valley bio-industry On the basis of industry-oriented in the past, it will strengthen scientific and technological innovation, “through the construction of major infrastructure, attract more talents to come here to innovate and start businesses, and build the Optics Valley Innovative Drug Industry Base into a scientific and technological source of biopharmaceuticals. , the place where achievements are produced, and realize the sustainable development of Optics Valley Bio-city.”
(Hubei TV reporter: Xia Xiaoqing; correspondent : Wu Fei)
[Source: Voice of Hubei]
Disclaimer: This article is reproduced for the purpose of conveying more information. If the source is incorrectly marked or infringes your legal rights, please contact the author with the ownership certificate, we will correct or delete it in time, thank you. Email address: [email protected]